Profile data is unavailable for this security.
About the company
AlloVir, Inc. is an allogeneic T cell immunotherapy company with a focus on restoring natural immunity against life-threatening viral diseases in pediatric and adult patients with weakened immune systems. The company’s proprietary technology platforms leverage off-the-shelf, allogeneic, single- and multi-virus-specific T cells for patients with T cell deficiencies who are at risk from the life-threatening consequences of viral diseases. Its technology and manufacturing process enable the potential for the treatment and prevention of a spectrum of devastating viruses with each single allogeneic cell therapy. Its lead product candidate, posoleucel, is a multi-VST therapy that targets six viruses: adenovirus (BKV), cytomegalovirus (EBV), human herpesvirus 6 (HHV-6) and JC virus (JCV). Its proprietary VST manufacturing platform enables the rapid, robust and reproducible generation of single-virus and multi-virus specific cell therapeutic candidates for clinical use.
- Revenue in USD (TTM)0.00
- Net income in USD-140.34m
- Incorporated2013
- Employees112.00
- LocationAllovir Inc1100 Winter StreetWALTHAM 02451United StatesUSA
- Phone+1 (617) 433-2605
- Fax+1 (302) 655-5049
- Websitehttps://www.allovir.com
More ▼
Mergers & acquisitions
| Acquired company | ALVR:NAQ since announced | Transaction value |
|---|---|---|
| Kalaris Therapeutics Inc | -36.84% | 347.00m |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Prelude Therapeutics Inc | 3.00m | -131.52m | 65.49m | 128.00 | -- | 0.3209 | -- | 21.83 | -1.77 | -1.77 | 0.0404 | 3.71 | 0.0132 | -- | -- | 23,437.50 | -57.72 | -47.21 | -63.14 | -51.07 | -- | -- | -4,383.90 | -- | -- | -- | 0.0023 | -- | -- | -- | -5.54 | -- | 46.03 | -- |
| Vor Biopharma Inc | 0.00 | -118.09m | 65.53m | 168.00 | -- | 0.6677 | -- | -- | -1.74 | -1.74 | 0.00 | 1.43 | 0.00 | -- | -- | 0.00 | -60.16 | -45.79 | -64.52 | -48.98 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -27.98 | -- | -- | -- |
| Maia Biotechnology Inc | 0.00 | -28.08m | 69.57m | 13.00 | -- | 21.85 | -- | -- | -1.62 | -1.62 | 0.00 | 0.1332 | 0.00 | -- | -- | 0.00 | -251.96 | -- | -362.21 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -21.91 | -- | -- | -- |
| Syros Pharmaceuticals Inc | 386.00k | -97.82m | 70.03m | 68.00 | -- | -- | -- | 181.43 | -3.03 | -3.03 | 0.0105 | -0.4145 | 0.0033 | -- | -- | 5,676.47 | -84.04 | -54.44 | -111.15 | -64.32 | -- | -- | -25,340.67 | -772.82 | -- | -179.01 | 1.37 | -- | -33.23 | 37.12 | -73.87 | -- | -27.78 | -- |
| Spero Therapeutics Inc | 118.46m | 17.46m | 71.34m | 46.00 | 4.17 | 0.8856 | 4.05 | 0.6023 | 0.3169 | 0.3169 | 2.21 | 1.49 | 0.9524 | -- | 4.11 | 2,575,196.00 | 14.03 | -35.52 | 18.79 | -41.75 | -- | -- | 14.74 | -124.40 | -- | -- | 0.00 | -- | 93.95 | 92.11 | 149.14 | -- | -- | -- |
| Allovir Inc | 0.00 | -140.34m | 71.41m | 112.00 | -- | 0.5934 | -- | -- | -1.23 | -1.23 | 0.00 | 1.04 | 0.00 | -- | -- | 0.00 | -67.85 | -52.85 | -73.72 | -57.72 | -- | -- | -- | -378,613.90 | -- | -- | 0.00 | -- | -- | -- | -12.87 | -- | -- | -- |
| IO Biotech Inc | 0.00 | -88.00m | 72.47m | 68.00 | -- | 0.7528 | -- | -- | -1.44 | -1.44 | 0.00 | 1.46 | 0.00 | -- | -- | 0.00 | -76.85 | -- | -86.10 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -20.47 | -- | -- | -- |
| Quince Therapeutics Inc | 0.00 | -53.12m | 73.57m | 32.00 | -- | 1.57 | -- | -- | -1.27 | -1.27 | 0.00 | 1.09 | 0.00 | -- | -- | 0.00 | -47.50 | -42.72 | -50.26 | -46.06 | -- | -- | -- | -- | -- | -- | 0.2275 | -- | -- | -- | 39.25 | -- | -5.47 | -- |
| Citius Pharmaceuticals Inc | 0.00 | -39.77m | 74.37m | 22.00 | -- | 0.8679 | -- | -- | -0.2443 | -0.2443 | 0.00 | 0.4741 | 0.00 | -- | -- | 0.00 | -36.91 | -30.26 | -39.00 | -32.11 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -0.1589 | -- | -- | -- |
| Medicinova Inc | 1.00m | -8.16m | 75.04m | 13.00 | -- | 1.31 | -- | 75.04 | -0.1665 | -0.1665 | 0.0204 | 1.17 | 0.0155 | -- | -- | 76,923.08 | -12.65 | -15.36 | -13.19 | -15.90 | -- | -- | -816.49 | -1,182.54 | -- | -- | 0.00 | -- | -- | -- | 39.08 | -- | 15.87 | -- |
| Metagenomi Inc | 55.93m | -75.00m | 75.68m | 228.00 | -- | 0.2809 | -- | 1.35 | -2.53 | -2.53 | 1.68 | 7.19 | 0.1408 | -- | 28.13 | 236,987.30 | -18.88 | -- | -22.14 | -- | -- | -- | -134.10 | -- | -- | -- | 0.00 | -- | 160.21 | -- | -56.57 | -- | -- | -- |
| ALX Oncology Holdings Inc | 0.00 | -171.44m | 76.37m | 74.00 | -- | 0.4774 | -- | -- | -3.64 | -3.64 | 0.00 | 3.04 | 0.00 | -- | -- | 0.00 | -74.45 | -34.34 | -84.76 | -36.47 | -- | -- | -- | -7,238.76 | -- | -- | 0.0734 | -- | -- | -- | -30.23 | -- | 14.30 | -- |
| Boundless Bio Inc | 0.00 | -57.72m | 77.89m | 72.00 | -- | 0.4346 | -- | -- | -2.60 | -2.60 | 0.00 | 8.05 | 0.00 | -- | -- | 0.00 | -33.64 | -- | -35.41 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -7.70 | -- | -- | -- |
| Inotiv Inc | 501.06m | -99.22m | 78.02m | 1.96k | -- | 0.4284 | -- | 0.1557 | -3.84 | -3.84 | 19.44 | 7.00 | 0.615 | 8.12 | 6.83 | 256,297.70 | -12.11 | -23.84 | -19.28 | -29.26 | 24.93 | 29.31 | -19.70 | -33.24 | 0.2279 | -0.6234 | 0.6774 | -- | 4.52 | 85.10 | 68.80 | -- | 83.64 | -- |
| Celularity Inc | 33.52m | -154.29m | 78.05m | 120.00 | -- | 2.48 | -- | 2.33 | -8.19 | -8.19 | 1.77 | 1.43 | 0.1324 | 3.41 | 3.19 | 279,308.30 | -60.96 | -19.19 | -82.57 | -20.99 | 53.30 | -- | -460.34 | -454.79 | 0.29 | 8.56 | 0.5602 | -- | 26.68 | -- | -1,483.14 | -- | -- | -- |
| Beyondspring Inc | 1.88m | -15.57m | 78.18m | 35.00 | -- | -- | -- | 41.68 | -0.3987 | -0.3987 | 0.0481 | -0.749 | 0.0698 | -- | -- | 52,111.11 | -59.75 | -75.50 | -102.15 | -96.48 | -- | -- | -856.29 | -4,977.12 | -- | -- | -- | -- | 29.61 | -- | 36.82 | -- | -13.54 | -- |
Data as of Nov 08 2024. Currency figures normalised to Allovir Inc's reporting currency: US Dollar USD
35.20%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| EcoR1 Capital, LLCas of 30 Jun 2024 | 11.29m | 9.79% |
| Octagon Capital Advisors LPas of 30 Sep 2024 | 11.20m | 9.71% |
| Invus Public Equities Advisors LLCas of 25 Jul 2024 | 6.60m | 5.72% |
| Millennium Management LLCas of 30 Jun 2024 | 3.30m | 2.86% |
| The Vanguard Group, Inc.as of 30 Jun 2024 | 2.63m | 2.28% |
| Redmile Group LLCas of 30 Jun 2024 | 1.91m | 1.65% |
| Acadian Asset Management LLCas of 30 Jun 2024 | 1.18m | 1.02% |
| Acuitas Investments LLCas of 30 Sep 2024 | 1.07m | 0.93% |
| Renaissance Technologies LLCas of 30 Jun 2024 | 791.20k | 0.69% |
| Geode Capital Management LLCas of 30 Jun 2024 | 647.48k | 0.56% |
More ▼
Data from 30 Jun 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
